Duloxetine in the treatment of binge eating disorder with depressive disorders: A placebo-controlled trial

Objective: This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. Method: In this 12‐week, double‐blind, placebo‐controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders‐IV‐TR BED and a comorbid curr...

Full description

Saved in:
Bibliographic Details
Published inThe International journal of eating disorders Vol. 45; no. 2; pp. 281 - 289
Main Authors Guerdjikova, Anna I., McElroy, Susan L., Winstanley, Erin L., Nelson, Eric B., Mori, Nicole, McCoy, Jessica, Keck Jr, Paul E., Hudson, James I.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2012
Wiley Subscription Services, Inc
Subjects
Adolescent
Adult
Aged
Antidepressive Agents - therapeutic use
Binge eating
binge eating disorder
Binge-Eating Disorder - complications
Binge-Eating Disorder - drug therapy
Bulimia
Clinical outcomes
depression
Depressive Disorder - complications
Depressive Disorder - drug therapy
Double-Blind Method
Drug therapy
duloxetine
Duloxetine Hydrochloride
Eating disorders
Female
Humans
Inhibitor drugs
longitudinal analysis
Male
Mental depression
Middle Aged
obesity
Thiophenes - therapeutic use
Treatment Outcome
Online AccessGet full text

Cover

Abstract Objective: This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. Method: In this 12‐week, double‐blind, placebo‐controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders‐IV‐TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency. Results: In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression‐Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups. Discussion: Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo‐controlled trials. © 2011 by Wiley Periodicals, Inc. (Int J Eat Disord 2012)
AbstractList This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. In this 12-week, double-blind, placebo-controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders-IV-TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency. In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression-Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups. Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo-controlled trials.
Objective: This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. Method: In this 12‐week, double‐blind, placebo‐controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders‐IV‐TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency. Results: In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression‐Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups. Discussion: Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo‐controlled trials. © 2011 by Wiley Periodicals, Inc. (Int J Eat Disord 2012)
This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders.OBJECTIVEThis study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders.In this 12-week, double-blind, placebo-controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders-IV-TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency.METHODIn this 12-week, double-blind, placebo-controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders-IV-TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency.In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression-Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups.RESULTSIn the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression-Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups.Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo-controlled trials.DISCUSSIONDuloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo-controlled trials.
This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. In this 12-week, double-blind, placebo-controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders-IV-TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency. In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression-Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups. Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo-controlled trials.
Author Mori, Nicole
McCoy, Jessica
Winstanley, Erin L.
Keck Jr, Paul E.
McElroy, Susan L.
Guerdjikova, Anna I.
Hudson, James I.
Nelson, Eric B.
Author_xml – sequence: 1
  givenname: Anna I.
  surname: Guerdjikova
  fullname: Guerdjikova, Anna I.
  email: anna.guerdjikova@lindnercenter.org
  organization: Lindner Center of HOPE, Mason, Ohio
– sequence: 2
  givenname: Susan L.
  surname: McElroy
  fullname: McElroy, Susan L.
  organization: Lindner Center of HOPE, Mason, Ohio
– sequence: 3
  givenname: Erin L.
  surname: Winstanley
  fullname: Winstanley, Erin L.
  organization: Lindner Center of HOPE, Mason, Ohio
– sequence: 4
  givenname: Eric B.
  surname: Nelson
  fullname: Nelson, Eric B.
  organization: Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio
– sequence: 5
  givenname: Nicole
  surname: Mori
  fullname: Mori, Nicole
  organization: Lindner Center of HOPE, Mason, Ohio
– sequence: 6
  givenname: Jessica
  surname: McCoy
  fullname: McCoy, Jessica
  organization: Lindner Center of HOPE, Mason, Ohio
– sequence: 7
  givenname: Paul E.
  surname: Keck Jr
  fullname: Keck Jr, Paul E.
  organization: Lindner Center of HOPE, Mason, Ohio
– sequence: 8
  givenname: James I.
  surname: Hudson
  fullname: Hudson, James I.
  organization: Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, Massachusetts
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21744377$$D View this record in MEDLINE/PubMed
BookMark eNp1kU9vEzEQxS1URNPCgS-ALC6Iw7Ze22vvcotKaZEiKFL4c7O86zF1cNbBdmj77euQpIcKTiPN_N7TzJsjdDCGERB6WZOTmhB6CjqfUNJx8QRNatK1VU3aHwdoQqgUFeOyPURHKS0IIYKR5hk6pLXknEk5QYv3ax9uIbsRsBtxvgacY_FbwphxsLh340_ApVEqNi6FaCDiG5evsYFVhJTcH3gYpHd4ildeD9CHaghjjsF7MMXSaf8cPbXaJ3ixq8fo64fz-dllNft88fFsOqsGTrmotAYzGCCD5UJoyWirmSW2aVhTG0J621kDnPTlLtrzxkBdN9Z2AKIlpBMdO0Zvtr6rGH6vIWW1dGkA7_UIYZ1UR4lseStpIV8_IhdhHcey3AZqWUOZKNCrHbTul2DUKrqljndqn2EBTrfAEENKEawaXC6Bbc7XzquaqM2XVAlR_f1SUbx9pNib_ovdud84D3f_B9X5dL5XVFuFSxluHxQ6_lJCMtmo758u1FUj2i9X32Zqzu4BANew7Q
CODEN INDIDJ
CitedBy_id crossref_primary_10_1016_j_euroneuro_2024_03_006
crossref_primary_10_1016_j_psc_2019_01_007
crossref_primary_10_17816_CP6150
crossref_primary_10_1002_erv_2277
crossref_primary_10_1097_YIC_0000000000000079
crossref_primary_10_1080_14656566_2016_1198776
crossref_primary_10_1111_cts_13406
crossref_primary_10_1080_01677063_2017_1353092
crossref_primary_10_1007_s40265_014_0327_0
crossref_primary_10_1007_s11920_015_0573_1
crossref_primary_10_1016_j_jad_2016_10_035
crossref_primary_10_3389_fpsyt_2021_635502
crossref_primary_10_2147_JEP_S255376
crossref_primary_10_1080_15622975_2023_2245458
crossref_primary_10_1080_13543784_2019_1692813
crossref_primary_10_1002_osp4_619
crossref_primary_10_1155_2013_352865
crossref_primary_10_1002_eat_22104
crossref_primary_10_14336_ad_2014_0124
crossref_primary_10_1517_14656566_2012_721781
crossref_primary_10_7717_peerj_5113
crossref_primary_10_1007_s40263_018_0594_5
crossref_primary_10_1097_MD_0000000000023362
crossref_primary_10_1007_s40263_024_01111_1
crossref_primary_10_1038_s41366_021_01032_9
crossref_primary_10_1186_s12888_015_0445_6
crossref_primary_10_1016_j_jad_2023_06_068
crossref_primary_10_1080_14656566_2024_2428371
crossref_primary_10_1517_14656566_2015_1053465
crossref_primary_10_3389_fpsyt_2019_00772
crossref_primary_10_1097_WNF_0000000000000438
crossref_primary_10_4158_EP161365_GL
crossref_primary_10_1016_j_cct_2017_10_007
crossref_primary_10_26416_Psih_57_2_2019_2442
crossref_primary_10_1017_S1092852915000759
crossref_primary_10_1080_14737175_2023_2273392
crossref_primary_10_14341_omet12714
crossref_primary_10_1007_s40261_016_0381_3
crossref_primary_10_1007_s40519_013_0003_5
crossref_primary_10_1186_s12888_024_05943_5
crossref_primary_10_1177_02698811211032475
crossref_primary_10_3390_nu16050594
crossref_primary_10_1007_s12325_017_0613_9
crossref_primary_10_3389_fnut_2017_00015
crossref_primary_10_1007_s40501_014_0023_4
crossref_primary_10_1111_acps_12502
crossref_primary_10_1002_eat_23297
crossref_primary_10_1016_j_chc_2012_07_003
crossref_primary_10_1002_erv_2517
crossref_primary_10_1016_j_jad_2021_03_032
crossref_primary_10_2174_1874205X01913010022
crossref_primary_10_3390_ijms222011086
crossref_primary_10_1097_YCO_0000000000000358
crossref_primary_10_1517_14728214_2014_879291
crossref_primary_10_1002_eat_22722
Cites_doi 10.4088/JCP.v63n1113
10.2147/NDT.S2505
10.4088/JCP.v63n0909
10.1016/j.biopsych.2006.03.040
10.1007/BF02850181
10.1002/hup.1040
10.1002/hup.696
10.1111/j.2044-8341.1959.tb00467.x
10.1016/S0924-977X(02)00126-8
10.4088/JCP.v69n0213
10.1177/0269881108098822
10.1002/eat.20539
10.1002/hup.899
10.1001/archpsyc.1989.01810110048007
10.1176/ajp.2006.163.12.2181
10.1016/j.biopsych.2005.09.018
10.2165/11318930-000000000-00000
10.1097/FBP.0b013e3282f3cf70
10.1002/eat.20719
10.1016/j.pnpbp.2009.09.016
10.1097/JCP.0b013e318160d5e6
10.4088/JCP.v67n1209
10.1001/archpsyc.1993.01820210073009
10.1176/appi.ajp.2007.06121970
10.1002/eat.20174
10.1016/j.brat.2005.01.004
10.4088/JCP.v68n0306
10.1016/j.appet.2009.05.018
10.1176/appi.ajp.160.2.255
10.1017/S0033291703001107
10.1016/0165-1781(86)90060-0
10.1016/0022-3999(85)90010-8
10.4088/JCP.v64n0711
10.1001/archpsyc.60.11.1109
10.1176/appi.ajp.157.6.1004
10.1177/0269881106060502
10.1093/oxfordhb/9780195373622.013.0024
10.1097/YIC.0b013e328329c7b5
10.1345/aph.1G101
10.1002/eat.20599
10.1037/1064-1297.15.5.481
ContentType Journal Article
Copyright Copyright © 2011 Wiley Periodicals, Inc.
Copyright Wiley Periodicals Inc. Mar 2012
Copyright_xml – notice: Copyright © 2011 Wiley Periodicals, Inc.
– notice: Copyright Wiley Periodicals Inc. Mar 2012
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TS
K9.
7X8
DOI 10.1002/eat.20946
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Physical Education Index
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Physical Education Index
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Psychology
Diet & Clinical Nutrition
EISSN 1098-108X
EndPage 289
ExternalDocumentID 2582848771
21744377
10_1002_eat_20946
EAT20946
ark_67375_WNG_P568QPVL_T
Genre miscellaneous
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
Feature
GrantInformation_xml – fundername: Eli Lilly
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
2FS
31~
33P
36B
3SF
3WU
4.4
41~
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
A03
A8Z
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABGFU
ABIJN
ABIVO
ABJNI
ABPVW
ABQWH
ABTAH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACHQT
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BKOMP
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
EPS
ESTFP
ESX
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.T
H.X
HAOEW
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6U
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSMAN
MSSTM
MVM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NHB
NNB
O66
O9-
OHT
OIG
OVD
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RVT
RWI
RX1
SAMSI
SUPJJ
SV3
TAE
TEORI
TN5
TUS
UB1
UHB
UMD
UPT
V2E
V62
V8K
VQA
W8V
W99
WBKPD
WH7
WHDPE
WHG
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRC
WSUWO
WXSBR
XG1
XJT
XSW
XV2
YCJ
YZZ
Z0I
ZCA
ZGI
ZXP
ZY4
ZZTAW
~IA
~KM
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACUHS
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
ADXHL
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7TS
K9.
7X8
ID FETCH-LOGICAL-c4246-aaedcde0cf466a7328a3f0f55351d00bf9fde40b3472b45de115ff9ee68009693
IEDL.DBID DR2
ISSN 0276-3478
1098-108X
IngestDate Fri Jul 11 05:11:47 EDT 2025
Sun Jul 13 05:18:48 EDT 2025
Mon Jul 21 06:04:45 EDT 2025
Tue Jul 01 03:13:19 EDT 2025
Thu Apr 24 22:59:18 EDT 2025
Wed Jan 22 16:21:59 EST 2025
Wed Oct 30 09:51:12 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
Copyright © 2011 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4246-aaedcde0cf466a7328a3f0f55351d00bf9fde40b3472b45de115ff9ee68009693
Notes Supported in part by a grant from Eli Lilly.
ArticleID:EAT20946
Paul Keck Jr, MD, is employed by the University of Cincinnati College of Medicine, University of Cincinnati Physicians, and the Lindner Center of HOPE; Dr. Keck is presently or has been in the past year a principal or co-investigator on research studies sponsored by Alkermes, AstraZeneca, Cephalon, GlaxoSmithKline, Eli Lilly and Company, Epi-Q, Jazz Pharmaceuticals, Marriott Foundation, National Institute of Mental Health (NIMH), Orexigen, Pfizer, Shire; Dr. Keck has been reimbursed for consulting to, in the past year: 2010: Sepracor, Medco, 2009: BristolMyersSquibb, GlaxoSmithKline, Pfizer, QuantiaMD, Schering Plough, Patents: Dr. Paul E. Keck Jr. is a co-inventor on United States Patent No. 6,387,956: Shapira NA, Goldsmith TD, Keck, PE Jr. (University of Cincinnati) Methods of treating obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual. Filed March 25, 1999; approved May 14, 2002; Dr. Keck has received no financial gain from this patent. Susan L. McElroy, MD, is employed by the University of Cincinnati College of Medicine, University of Cincinnati Physicians, and the Lindner Center of HOPE; Dr. McElroy is a consultant to, or member of the scientific advisory boards of Alkermes, Eli Lilly and Company, Shire; Dr. McElroy is a principal or co-investigator on research studies sponsored by Agency for Healthcare Research & Quality (AHRQ), Alkermes, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, Forest Labs, GalaxoSmith Kline, Jazz Pharmaceuticals, Marriott Foundation, National Institute of Mental Health, Orexigen Therapeutics, Pfizer Shire, Takeda Pharmaceutical Company Limited; Patents: Dr. Susan L. McElroy is also inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and, along with the patent's assignee, University of Cincinnati, Cincinnati, OH, has received payments from Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has exclusive rights under the patent. James I. Hudson, MD, has been a consultant for Eli Lilly, Pfizer, and Alkermes; and has received grant support from Eli Lilly, Otsuka, and Ortho-McNeil Janssen Scientific Affairs. Erik B. Nelson, MD, has received funding for clinical trials with Astra Zeneca, Novartis and Pamlab. Drs. Erin L. Winstanley and Anna I. Guerdjikova and Mrs. Nicole Mori and Jessica McCoy have no industry/commercial support or conflicts of interest to disclose.
Eli Lilly
ark:/67375/WNG-P568QPVL-T
istex:3B2C4D6CB10A3892E61794AD50237BE26B0DD1FF
Paul Keck Jr, MD, is employed by the University of Cincinnati College of Medicine, University of Cincinnati Physicians, and the Lindner Center of HOPE; Dr. Keck is presently or has been in the past year a principal or co‐investigator on research studies sponsored by Alkermes, AstraZeneca, Cephalon, GlaxoSmithKline, Eli Lilly and Company, Epi‐Q, Jazz Pharmaceuticals, Marriott Foundation, National Institute of Mental Health (NIMH), Orexigen, Pfizer, Shire; Dr. Keck has been reimbursed for consulting to, in the past year: 2010: Sepracor, Medco, 2009: BristolMyersSquibb, GlaxoSmithKline, Pfizer, QuantiaMD, Schering Plough, Patents: Dr. Paul E. Keck Jr. is a co‐inventor on United States Patent No. 6,387,956: Shapira NA, Goldsmith TD, Keck, PE Jr. (University of Cincinnati) Methods of treating obsessive‐compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual. Filed March 25, 1999; approved May 14, 2002; Dr. Keck has received no financial gain from this patent. Susan L. McElroy, MD, is employed by the University of Cincinnati College of Medicine, University of Cincinnati Physicians, and the Lindner Center of HOPE; Dr. McElroy is a consultant to, or member of the scientific advisory boards of Alkermes, Eli Lilly and Company, Shire; Dr. McElroy is a principal or co‐investigator on research studies sponsored by Agency for Healthcare Research & Quality (AHRQ), Alkermes, AstraZeneca, Bristol‐Myers Squibb, Cephalon, Eli Lilly and Company, Forest Labs, GalaxoSmith Kline, Jazz Pharmaceuticals, Marriott Foundation, National Institute of Mental Health, Orexigen Therapeutics, Pfizer Shire, Takeda Pharmaceutical Company Limited; Patents: Dr. Susan L. McElroy is also inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and, along with the patent's assignee, University of Cincinnati, Cincinnati, OH, has received payments from Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has exclusive rights under the patent. James I. Hudson, MD, has been a consultant for Eli Lilly, Pfizer, and Alkermes; and has received grant support from Eli Lilly, Otsuka, and Ortho‐McNeil Janssen Scientific Affairs. Erik B. Nelson, MD, has received funding for clinical trials with Astra Zeneca, Novartis and Pamlab. Drs. Erin L. Winstanley and Anna I. Guerdjikova and Mrs. Nicole Mori and Jessica McCoy have no industry/commercial support or conflicts of interest to disclose.
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/eat.20946
PMID 21744377
PQID 920835236
PQPubID 49031
PageCount 9
ParticipantIDs proquest_miscellaneous_920784872
proquest_journals_920835236
pubmed_primary_21744377
crossref_citationtrail_10_1002_eat_20946
crossref_primary_10_1002_eat_20946
wiley_primary_10_1002_eat_20946_EAT20946
istex_primary_ark_67375_WNG_P568QPVL_T
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-03
March 2012
2012-03-00
2012-Mar
20120301
PublicationDateYYYYMMDD 2012-03-01
PublicationDate_xml – month: 03
  year: 2012
  text: 2012-03
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: United States
PublicationTitle The International journal of eating disorders
PublicationTitleAlternate Int. J. Eat. Disord
PublicationYear 2012
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley Subscription Services, Inc
References Noma S,Uwatoko T,Yamamoto H,Hayashi T. Effects of milnacipran on binge eating-A pilot study. Neuropsychiatr Dis Treat 2008; 4: 295-300.
Ji D,Gilpin NW,Richardson HN,Rivier CL,Koob GF. Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 2008; 19: 1-12.
Davis C,Carter JC. Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite 2009; 53: 1-8.
Fichter MM,Quadflieg N,Hedlund S. Long-term course of binge eating disorder and bulimia nervosa: Relevance for nosology and diagnostic criteria. Int J Eat Disord 2008; 41: 577-586.
Stunkard AJ,Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985; 29: 71-83.
McElroy SL,Guerdjikova A,Kotwal R,Welge JA,Nelson EB,Lake KA, et al. Atomoxetine in the treatment of binge-eating disorder: A randomized placebo-controlled trial. J Clin Psychiatry 2007; 68: 390-398.
Guy W. ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health, 1976.
Christensen RC,Averbuch RN. The use of duloxetine in chronic bulimia nervosa: A case report. Psychiatry (Edgmont) 2009; 6: 27-28.
Pope HGJr,Lalonde JK,Pindyck LJ,Walsh T,Bulik CM,Crow SJ, et al. Binge eating disorder: A stable syndrome. Am J Psychiatry 2006; 163: 2181-2183.
El-Giamal N,de Zwaan M,Bailer U,Strnad A,Schussler P,Kasper S. Milnacipran in the treatment of bulimia nervosa: A report of 16 cases. Eur Neuropsychopharmacol 2003; 13: 73-79.
McElroy S,Guerdjikova A,O'Melia A. The oxford handbook of eating disorders: Pharmacotherapy of the eating disorders. New York, NY: Oxford University Press, 2010, pp. 417-451.
Gibbons RD,Hedeker D,Elkin I,Waternaux C,Kraemer HC,Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739-750.
Gartlehner G,Thaler K,Hansen RA,Gaynes BN. The general and comparative efficacy and safety of duloxetine in major depressive disorder: A systematic review and meta-analysis. Drug Saf 2009; 32: 1159-1173.
McElroy SL,Hudson JI,Malhotra S,Welge JA,Nelson EB,Keck PEJr. Citalopram in the treatment of binge-eating disorder: A placebo-controlled trial. J Clin Psychiatry 2003; 64: 807-813.
Lai CH. Duloxetine related binge eating behaviors: A case report. Prog Neuro-Psychopharmacol Biol Psychiatry 2009; 33: 1581-1582.
Perroud N,Relecom C,Huguelet P. Successful treatment of nicotine withdrawal with duloxetine: A case report. J Clin Psychopharmacol 2008; 28: 102-104.
Milano W,Petrella C,Casella A,Capasso A,Carrino S,Milano L. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study. Adv Ther 2005; 22: 25-31.
Leombruni P,Lavagnino L,Gastaldi F,Vasile A,Fassino S. Duloxetine in obese binge eater outpatients: Preliminary results from a 12-week open trial. Hum Psychopharmacol 2009; 24: 483-488.
Marcil WA,Petty F. Duloxetine associated with smoking cessation. Ann Pharmacother 2005; 39: 1578-1579.
Malhotra S,King KH,Welge JA,Brusman-Lovins L,McElroy SL. Venlafaxine treatment of binge-eating disorder associated withobesity: A series of 35 patients. J Clin Psychiatry 2002; 63: 802-806.
Peterson CB,Miller KB,Crow SJ,Thuras P,Mitchell JE. Subtypes of binge eating disorder based on psychiatric history. Int J Eat Disord 2005; 38: 273-276.
Bernardi S,Pallanti S. Successful duloxetine treatment of a binge eating disorder: A case report. J Psychopharmacol 2008; 24: 1269-1272.
McElroy SL,Casuto LS,Nelson EB,Lake KA,Soutullo CA,Keck PEJr,Hudson JI. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000; 157: 1004-1006.
A.P.A. Diagnostic and statistical manual of mental disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 2000, pp. 785-787.
Javaras KN,Pope HG,Lalonde JK,Roberts JL,Nillni YI,Laird NM, et al. Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry 2008; 69: 266-273.
Fitzmaurice G,Laird NMWare JH. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons, 2004, pp. 60-72.
Hudson JI,Wohlreich MM,Kajdasz DK,Mallinckrodt CH,Watkin JG,Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: Analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005; 20: 327-341.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
McElroy SL,Arnold LM,Shapira NA,Keck PEJr,Rosenthal NR,Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255-261.
Wilfley DE,Crow SJ,Hudson JI,Mitchell JE,Berkowitz RI,Blakesley V, et al. Efficacy of sibutramine for the treatment of binge eating disorder: A randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008; 165: 51-58.
Grilo CM,White MA,Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord 2009; 42: 228-234.
Hudson JI,Hiripi E,Pope HGJr,Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 61: 348-358.
Guerdjikova AI,McElroy SL,Welge JA,Nelson E,Keck PE,Hudson JI. Lamotrigine in the treatment of binge-eating disorder with obesity: A randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol 2009; 24: 150-158.
Goodman WK,Price LH,Rasmussen SA,Mazure C,Fleischmann RL,Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011.
Reas DL,Grilo CM,Masheb RM. Reliability of the Eating Disorder Examination-Questionnaire in patients with binge eating disorder. Behav Res Ther 2006; 44: 43-51.
First M,Spitzer R,Gibbon M,Williams J. Structured Clinical Interview for DSM-IV-TR Axis I disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 2002.
Trivedi MH,Rush AJ,Ibrahim HM,Carmody TJ,Biggs MM,Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004; 34: 73-82.
Rush AJ,Giles DE,Schlesser MA,Fulton CL,Weissenburger J,Burns C. The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 1986; 18: 65-87.
McElroy SL,Kotwal R,Guerdjikova AI,Welge JA,Nelson EB,Lake KA, et al. Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial. J Clin Psychiatry 2006; 67: 1897-1906.
Nestler EJ,Carlezon WAJr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-1159.
Arnold LM,McElroy SL,Hudson JI,Welge JA,Bennett AJ,Keck PE. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002; 63: 1028-1033.
Hazen E,Fava M. Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: A case report. J Psychopharmacol 2006; 20: 723-724.
Wonderlich SA,Gordon KH,Mitchell JE,Crosby RD,Engel SG. The validity and clinical utility of binge eating disorder. Int JEat Disord 2009; 42: 687-705.
Appolinario JC,Bacaltchuk J,Sichieri R,Claudino AM,Godoy-Matos A,Morgan C, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60: 1109-1116.
Avena NM. Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Exp Clin Psychopharmacol 2007; 15: 481-491.
Guerdjikova AI,McElroy SL,Kotwal R,Welge JA,Nelson E,Lake K, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: A placebo-controlled monotherapy trial. Hum Psychopharmacol 2008; 23: 1-11.
2009; 24
1985; 29
2009; 42
2000; 157
2010
2008; 19
2006; 59
2003; 13
1976
2005; 20
1986; 18
2004
2008; 4
2002
2008; 165
1989; 46
2005; 22
2007; 15
2009; 33
2006; 20
2009; 32
2009; 53
2002; 63
2006; 67
2000
1993; 50
2006; 44
2004; 34
2008; 28
2006; 163
2008; 69
2003; 160
2008; 23
2008; 24
2007; 61
2009; 6
2008; 41
2003; 60
2005; 38
2005; 39
1959; 32
2003; 64
2007; 68
e_1_2_6_31_2
e_1_2_6_30_2
e_1_2_6_18_2
e_1_2_6_19_2
e_1_2_6_12_2
e_1_2_6_35_2
e_1_2_6_13_2
e_1_2_6_34_2
e_1_2_6_10_2
e_1_2_6_11_2
e_1_2_6_32_2
e_1_2_6_39_2
e_1_2_6_17_2
e_1_2_6_38_2
e_1_2_6_14_2
e_1_2_6_37_2
e_1_2_6_15_2
e_1_2_6_36_2
(e_1_2_6_2_2) 2000
e_1_2_6_42_2
Pope HG (e_1_2_6_6_2) 2006; 163
e_1_2_6_20_2
e_1_2_6_41_2
e_1_2_6_40_2
Christensen RC (e_1_2_6_16_2) 2009; 6
Fitzmaurice G (e_1_2_6_33_2) 2004
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_9_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_5_2
e_1_2_6_24_2
e_1_2_6_47_2
e_1_2_6_23_2
First M (e_1_2_6_27_2) 2002
e_1_2_6_48_2
e_1_2_6_22_2
e_1_2_6_49_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_43_2
e_1_2_6_44_2
e_1_2_6_26_2
Guy W (e_1_2_6_29_2) 1976
e_1_2_6_45_2
e_1_2_6_25_2
e_1_2_6_46_2
References_xml – reference: Trivedi MH,Rush AJ,Ibrahim HM,Carmody TJ,Biggs MM,Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004; 34: 73-82.
– reference: Hudson JI,Hiripi E,Pope HGJr,Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 61: 348-358.
– reference: Gartlehner G,Thaler K,Hansen RA,Gaynes BN. The general and comparative efficacy and safety of duloxetine in major depressive disorder: A systematic review and meta-analysis. Drug Saf 2009; 32: 1159-1173.
– reference: El-Giamal N,de Zwaan M,Bailer U,Strnad A,Schussler P,Kasper S. Milnacipran in the treatment of bulimia nervosa: A report of 16 cases. Eur Neuropsychopharmacol 2003; 13: 73-79.
– reference: Guerdjikova AI,McElroy SL,Kotwal R,Welge JA,Nelson E,Lake K, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: A placebo-controlled monotherapy trial. Hum Psychopharmacol 2008; 23: 1-11.
– reference: A.P.A. Diagnostic and statistical manual of mental disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 2000, pp. 785-787.
– reference: Leombruni P,Lavagnino L,Gastaldi F,Vasile A,Fassino S. Duloxetine in obese binge eater outpatients: Preliminary results from a 12-week open trial. Hum Psychopharmacol 2009; 24: 483-488.
– reference: Bernardi S,Pallanti S. Successful duloxetine treatment of a binge eating disorder: A case report. J Psychopharmacol 2008; 24: 1269-1272.
– reference: Wilfley DE,Crow SJ,Hudson JI,Mitchell JE,Berkowitz RI,Blakesley V, et al. Efficacy of sibutramine for the treatment of binge eating disorder: A randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008; 165: 51-58.
– reference: Rush AJ,Giles DE,Schlesser MA,Fulton CL,Weissenburger J,Burns C. The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 1986; 18: 65-87.
– reference: Lai CH. Duloxetine related binge eating behaviors: A case report. Prog Neuro-Psychopharmacol Biol Psychiatry 2009; 33: 1581-1582.
– reference: Milano W,Petrella C,Casella A,Capasso A,Carrino S,Milano L. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study. Adv Ther 2005; 22: 25-31.
– reference: Avena NM. Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Exp Clin Psychopharmacol 2007; 15: 481-491.
– reference: Perroud N,Relecom C,Huguelet P. Successful treatment of nicotine withdrawal with duloxetine: A case report. J Clin Psychopharmacol 2008; 28: 102-104.
– reference: Arnold LM,McElroy SL,Hudson JI,Welge JA,Bennett AJ,Keck PE. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002; 63: 1028-1033.
– reference: Marcil WA,Petty F. Duloxetine associated with smoking cessation. Ann Pharmacother 2005; 39: 1578-1579.
– reference: McElroy SL,Arnold LM,Shapira NA,Keck PEJr,Rosenthal NR,Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255-261.
– reference: Javaras KN,Pope HG,Lalonde JK,Roberts JL,Nillni YI,Laird NM, et al. Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry 2008; 69: 266-273.
– reference: First M,Spitzer R,Gibbon M,Williams J. Structured Clinical Interview for DSM-IV-TR Axis I disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 2002.
– reference: McElroy S,Guerdjikova A,O'Melia A. The oxford handbook of eating disorders: Pharmacotherapy of the eating disorders. New York, NY: Oxford University Press, 2010, pp. 417-451.
– reference: McElroy SL,Casuto LS,Nelson EB,Lake KA,Soutullo CA,Keck PEJr,Hudson JI. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000; 157: 1004-1006.
– reference: Hudson JI,Wohlreich MM,Kajdasz DK,Mallinckrodt CH,Watkin JG,Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: Analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005; 20: 327-341.
– reference: McElroy SL,Hudson JI,Malhotra S,Welge JA,Nelson EB,Keck PEJr. Citalopram in the treatment of binge-eating disorder: A placebo-controlled trial. J Clin Psychiatry 2003; 64: 807-813.
– reference: Christensen RC,Averbuch RN. The use of duloxetine in chronic bulimia nervosa: A case report. Psychiatry (Edgmont) 2009; 6: 27-28.
– reference: Guerdjikova AI,McElroy SL,Welge JA,Nelson E,Keck PE,Hudson JI. Lamotrigine in the treatment of binge-eating disorder with obesity: A randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol 2009; 24: 150-158.
– reference: Grilo CM,White MA,Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord 2009; 42: 228-234.
– reference: Fitzmaurice G,Laird NMWare JH. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons, 2004, pp. 60-72.
– reference: Davis C,Carter JC. Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite 2009; 53: 1-8.
– reference: Guy W. ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health, 1976.
– reference: McElroy SL,Kotwal R,Guerdjikova AI,Welge JA,Nelson EB,Lake KA, et al. Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial. J Clin Psychiatry 2006; 67: 1897-1906.
– reference: McElroy SL,Guerdjikova A,Kotwal R,Welge JA,Nelson EB,Lake KA, et al. Atomoxetine in the treatment of binge-eating disorder: A randomized placebo-controlled trial. J Clin Psychiatry 2007; 68: 390-398.
– reference: Malhotra S,King KH,Welge JA,Brusman-Lovins L,McElroy SL. Venlafaxine treatment of binge-eating disorder associated withobesity: A series of 35 patients. J Clin Psychiatry 2002; 63: 802-806.
– reference: Stunkard AJ,Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985; 29: 71-83.
– reference: Nestler EJ,Carlezon WAJr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-1159.
– reference: Gibbons RD,Hedeker D,Elkin I,Waternaux C,Kraemer HC,Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739-750.
– reference: Fichter MM,Quadflieg N,Hedlund S. Long-term course of binge eating disorder and bulimia nervosa: Relevance for nosology and diagnostic criteria. Int J Eat Disord 2008; 41: 577-586.
– reference: Pope HGJr,Lalonde JK,Pindyck LJ,Walsh T,Bulik CM,Crow SJ, et al. Binge eating disorder: A stable syndrome. Am J Psychiatry 2006; 163: 2181-2183.
– reference: Reas DL,Grilo CM,Masheb RM. Reliability of the Eating Disorder Examination-Questionnaire in patients with binge eating disorder. Behav Res Ther 2006; 44: 43-51.
– reference: Peterson CB,Miller KB,Crow SJ,Thuras P,Mitchell JE. Subtypes of binge eating disorder based on psychiatric history. Int J Eat Disord 2005; 38: 273-276.
– reference: Hazen E,Fava M. Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: A case report. J Psychopharmacol 2006; 20: 723-724.
– reference: Wonderlich SA,Gordon KH,Mitchell JE,Crosby RD,Engel SG. The validity and clinical utility of binge eating disorder. Int JEat Disord 2009; 42: 687-705.
– reference: Goodman WK,Price LH,Rasmussen SA,Mazure C,Fleischmann RL,Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011.
– reference: Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
– reference: Appolinario JC,Bacaltchuk J,Sichieri R,Claudino AM,Godoy-Matos A,Morgan C, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60: 1109-1116.
– reference: Ji D,Gilpin NW,Richardson HN,Rivier CL,Koob GF. Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 2008; 19: 1-12.
– reference: Noma S,Uwatoko T,Yamamoto H,Hayashi T. Effects of milnacipran on binge eating-A pilot study. Neuropsychiatr Dis Treat 2008; 4: 295-300.
– volume: 50
  start-page: 739
  year: 1993
  end-page: 750
  article-title: Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset
  publication-title: Arch Gen Psychiatry
– volume: 63
  start-page: 802
  year: 2002
  end-page: 806
  article-title: Venlafaxine treatment of binge‐eating disorder associated withobesity: A series of 35 patients
  publication-title: J Clin Psychiatry
– volume: 69
  start-page: 266
  year: 2008
  end-page: 273
  article-title: Co‐occurrence of binge eating disorder with psychiatric and medical disorders
  publication-title: J Clin Psychiatry
– volume: 29
  start-page: 71
  year: 1985
  end-page: 83
  article-title: The three‐factor eating questionnaire to measure dietary restraint, disinhibition and hunger
  publication-title: J Psychosom Res
– volume: 39
  start-page: 1578
  year: 2005
  end-page: 1579
  article-title: Duloxetine associated with smoking cessation
  publication-title: Ann Pharmacother
– volume: 163
  start-page: 2181
  year: 2006
  end-page: 2183
  article-title: Binge eating disorder: A stable syndrome
  publication-title: Am J Psychiatry
– volume: 42
  start-page: 687
  year: 2009
  end-page: 705
  article-title: The validity and clinical utility of binge eating disorder
  publication-title: Int JEat Disord
– volume: 20
  start-page: 723
  year: 2006
  end-page: 724
  article-title: Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: A case report
  publication-title: J Psychopharmacol
– volume: 22
  start-page: 25
  year: 2005
  end-page: 31
  article-title: Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo‐controlled study
  publication-title: Adv Ther
– volume: 19
  start-page: 1
  year: 2008
  end-page: 12
  article-title: Effects of naltrexone, duloxetine, and a corticotropin‐releasing factor type 1 receptor antagonist on binge‐like alcohol drinking in rats
  publication-title: Behav Pharmacol
– volume: 61
  start-page: 348
  year: 2007
  end-page: 358
  article-title: The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
  publication-title: Biol Psychiatry
– volume: 53
  start-page: 1
  year: 2009
  end-page: 8
  article-title: Compulsive overeating as an addiction disorder. A review of theory and evidence
  publication-title: Appetite
– volume: 24
  start-page: 1269
  year: 2008
  end-page: 1272
  article-title: Successful duloxetine treatment of a binge eating disorder: A case report
  publication-title: J Psychopharmacol
– volume: 44
  start-page: 43
  year: 2006
  end-page: 51
  article-title: Reliability of the Eating Disorder Examination‐Questionnaire in patients with binge eating disorder
  publication-title: Behav Res Ther
– volume: 160
  start-page: 255
  year: 2003
  end-page: 261
  article-title: Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo‐controlled trial
  publication-title: Am J Psychiatry
– volume: 24
  start-page: 150
  year: 2009
  end-page: 158
  article-title: Lamotrigine in the treatment of binge‐eating disorder with obesity: A randomized, placebo‐controlled monotherapy trial
  publication-title: Int Clin Psychopharmacol
– start-page: 785
  year: 2000
  end-page: 787
– volume: 18
  start-page: 65
  year: 1986
  end-page: 87
  article-title: The Inventory for Depressive Symptomatology (IDS): Preliminary findings
  publication-title: Psychiatry Res
– volume: 68
  start-page: 390
  year: 2007
  end-page: 398
  article-title: Atomoxetine in the treatment of binge‐eating disorder: A randomized placebo‐controlled trial
  publication-title: J Clin Psychiatry
– volume: 157
  start-page: 1004
  year: 2000
  end-page: 1006
  article-title: Placebo‐controlled trial of sertraline in the treatment of binge eating disorder
  publication-title: Am J Psychiatry
– volume: 67
  start-page: 1897
  year: 2006
  end-page: 1906
  article-title: Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial
  publication-title: J Clin Psychiatry
– volume: 42
  start-page: 228
  year: 2009
  end-page: 234
  article-title: DSM‐IV psychiatric disorder comorbidity and its correlates in binge eating disorder
  publication-title: Int J Eat Disord
– volume: 63
  start-page: 1028
  year: 2002
  end-page: 1033
  article-title: A placebo‐controlled, randomized trial of fluoxetine in the treatment of binge‐eating disorder
  publication-title: J Clin Psychiatry
– volume: 38
  start-page: 273
  year: 2005
  end-page: 276
  article-title: Subtypes of binge eating disorder based on psychiatric history
  publication-title: Int J Eat Disord
– start-page: 417
  year: 2010
  end-page: 451
– volume: 64
  start-page: 807
  year: 2003
  end-page: 813
  article-title: Citalopram in the treatment of binge‐eating disorder: A placebo‐controlled trial
  publication-title: J Clin Psychiatry
– volume: 15
  start-page: 481
  year: 2007
  end-page: 491
  article-title: Examining the addictive‐like properties of binge eating using an animal model of sugar dependence
  publication-title: Exp Clin Psychopharmacol
– year: 2010
– volume: 165
  start-page: 51
  year: 2008
  end-page: 58
  article-title: Efficacy of sibutramine for the treatment of binge eating disorder: A randomized multicenter placebo‐controlled double‐blind study
  publication-title: Am J Psychiatry
– volume: 32
  start-page: 50
  year: 1959
  end-page: 55
  article-title: The assessment of anxiety states by rating
  publication-title: Br J Med Psychol
– start-page: 60
  year: 2004
  end-page: 72
– volume: 4
  start-page: 295
  year: 2008
  end-page: 300
  article-title: Effects of milnacipran on binge eating—A pilot study
  publication-title: Neuropsychiatr Dis Treat
– volume: 24
  start-page: 483
  year: 2009
  end-page: 488
  article-title: Duloxetine in obese binge eater outpatients: Preliminary results from a 12‐week open trial
  publication-title: Hum Psychopharmacol
– volume: 60
  start-page: 1109
  year: 2003
  end-page: 1116
  article-title: A randomized, double‐blind, placebo‐controlled study of sibutramine in the treatment of binge‐eating disorder
  publication-title: Arch Gen Psychiatry
– year: 2002
– volume: 23
  start-page: 1
  year: 2008
  end-page: 11
  article-title: High‐dose escitalopram in the treatment of binge‐eating disorder with obesity: A placebo‐controlled monotherapy trial
  publication-title: Hum Psychopharmacol
– volume: 46
  start-page: 1006
  year: 1989
  end-page: 1011
  article-title: The Yale‐Brown Obsessive Compulsive Scale. I. Development, use, and reliability
  publication-title: Arch Gen Psychiatry
– volume: 41
  start-page: 577
  year: 2008
  end-page: 586
  article-title: Long‐term course of binge eating disorder and bulimia nervosa: Relevance for nosology and diagnostic criteria
  publication-title: Int J Eat Disord
– volume: 34
  start-page: 73
  year: 2004
  end-page: 82
  article-title: The Inventory of Depressive Symptomatology, Clinician Rating (IDS‐C) and Self‐Report (IDS‐SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS‐C) and Self‐Report (QIDS‐SR) in public sector patients with mood disorders: A psychometric evaluation
  publication-title: Psychol Med
– volume: 28
  start-page: 102
  year: 2008
  end-page: 104
  article-title: Successful treatment of nicotine withdrawal with duloxetine: A case report
  publication-title: J Clin Psychopharmacol
– volume: 32
  start-page: 1159
  year: 2009
  end-page: 1173
  article-title: The general and comparative efficacy and safety of duloxetine in major depressive disorder: A systematic review and meta‐analysis
  publication-title: Drug Saf
– volume: 59
  start-page: 1151
  year: 2006
  end-page: 1159
  article-title: The mesolimbic dopamine reward circuit in depression
  publication-title: Biol Psychiatry
– volume: 33
  start-page: 1581
  year: 2009
  end-page: 1582
  article-title: Duloxetine related binge eating behaviors: A case report
  publication-title: Prog Neuro‐Psychopharmacol Biol Psychiatry
– volume: 13
  start-page: 73
  year: 2003
  end-page: 79
  article-title: Milnacipran in the treatment of bulimia nervosa: A report of 16 cases
  publication-title: Eur Neuropsychopharmacol
– year: 1976
– volume: 20
  start-page: 327
  year: 2005
  end-page: 341
  article-title: Safety and tolerability of duloxetine in the treatment of major depressive disorder: Analysis of pooled data from eight placebo‐controlled clinical trials
  publication-title: Hum Psychopharmacol
– volume: 6
  start-page: 27
  year: 2009
  end-page: 28
  article-title: The use of duloxetine in chronic bulimia nervosa: A case report
  publication-title: Psychiatry (Edgmont)
– ident: e_1_2_6_36_2
  doi: 10.4088/JCP.v63n1113
– ident: e_1_2_6_18_2
  doi: 10.2147/NDT.S2505
– ident: e_1_2_6_20_2
  doi: 10.4088/JCP.v63n0909
– ident: e_1_2_6_5_2
  doi: 10.1016/j.biopsych.2006.03.040
– volume-title: Structured Clinical Interview for DSM‐IV‐TR Axis I disorders, Research Version, Patient Edition (SCID‐I/P)
  year: 2002
  ident: e_1_2_6_27_2
– ident: e_1_2_6_21_2
– ident: e_1_2_6_23_2
  doi: 10.1007/BF02850181
– ident: e_1_2_6_13_2
  doi: 10.1002/hup.1040
– ident: e_1_2_6_25_2
  doi: 10.1002/hup.696
– ident: e_1_2_6_32_2
  doi: 10.1111/j.2044-8341.1959.tb00467.x
– ident: e_1_2_6_19_2
  doi: 10.1016/S0924-977X(02)00126-8
– ident: e_1_2_6_7_2
  doi: 10.4088/JCP.v69n0213
– ident: e_1_2_6_14_2
  doi: 10.1177/0269881108098822
– ident: e_1_2_6_8_2
  doi: 10.1002/eat.20539
– volume: 6
  start-page: 27
  year: 2009
  ident: e_1_2_6_16_2
  article-title: The use of duloxetine in chronic bulimia nervosa: A case report
  publication-title: Psychiatry (Edgmont)
– ident: e_1_2_6_41_2
  doi: 10.1002/hup.899
– ident: e_1_2_6_30_2
  doi: 10.1001/archpsyc.1989.01810110048007
– volume: 163
  start-page: 2181
  year: 2006
  ident: e_1_2_6_6_2
  article-title: Binge eating disorder: A stable syndrome
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.2006.163.12.2181
– ident: e_1_2_6_49_2
  doi: 10.1016/j.biopsych.2005.09.018
– ident: e_1_2_6_12_2
  doi: 10.2165/11318930-000000000-00000
– ident: e_1_2_6_45_2
  doi: 10.1097/FBP.0b013e3282f3cf70
– ident: e_1_2_6_3_2
  doi: 10.1002/eat.20719
– ident: e_1_2_6_15_2
  doi: 10.1016/j.pnpbp.2009.09.016
– ident: e_1_2_6_44_2
  doi: 10.1097/JCP.0b013e318160d5e6
– ident: e_1_2_6_39_2
  doi: 10.4088/JCP.v67n1209
– volume-title: ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare publication (ADM)
  year: 1976
  ident: e_1_2_6_29_2
– ident: e_1_2_6_34_2
  doi: 10.1001/archpsyc.1993.01820210073009
– ident: e_1_2_6_24_2
  doi: 10.1176/appi.ajp.2007.06121970
– ident: e_1_2_6_10_2
  doi: 10.1002/eat.20174
– ident: e_1_2_6_28_2
  doi: 10.1016/j.brat.2005.01.004
– ident: e_1_2_6_40_2
  doi: 10.4088/JCP.v68n0306
– ident: e_1_2_6_47_2
  doi: 10.1016/j.appet.2009.05.018
– start-page: 785
  volume-title: A.P.A. Diagnostic and statistical manual of mental disorders
  year: 2000
  ident: e_1_2_6_2_2
– start-page: 60
  volume-title: Applied Longitudinal Analysis
  year: 2004
  ident: e_1_2_6_33_2
– ident: e_1_2_6_38_2
  doi: 10.1176/appi.ajp.160.2.255
– ident: e_1_2_6_43_2
  doi: 10.1017/S0033291703001107
– ident: e_1_2_6_26_2
  doi: 10.1016/0165-1781(86)90060-0
– ident: e_1_2_6_31_2
  doi: 10.1016/0022-3999(85)90010-8
– ident: e_1_2_6_37_2
  doi: 10.4088/JCP.v64n0711
– ident: e_1_2_6_4_2
– ident: e_1_2_6_22_2
  doi: 10.1001/archpsyc.60.11.1109
– ident: e_1_2_6_35_2
  doi: 10.1176/appi.ajp.157.6.1004
– ident: e_1_2_6_17_2
  doi: 10.1177/0269881106060502
– ident: e_1_2_6_11_2
  doi: 10.1093/oxfordhb/9780195373622.013.0024
– ident: e_1_2_6_42_2
  doi: 10.1097/YIC.0b013e328329c7b5
– ident: e_1_2_6_46_2
  doi: 10.1345/aph.1G101
– ident: e_1_2_6_9_2
  doi: 10.1002/eat.20599
– ident: e_1_2_6_48_2
  doi: 10.1037/1064-1297.15.5.481
SSID ssj0006305
Score 2.2610223
Snippet Objective: This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. Method: In this 12‐week,...
This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. In this 12-week, double-blind,...
This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders. In this 12-week, double-blind,...
This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders.OBJECTIVEThis study evaluated...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 281
SubjectTerms Adolescent
Adult
Aged
Antidepressive Agents - therapeutic use
Binge eating
binge eating disorder
Binge-Eating Disorder - complications
Binge-Eating Disorder - drug therapy
Bulimia
Clinical outcomes
depression
Depressive Disorder - complications
Depressive Disorder - drug therapy
Double-Blind Method
Drug therapy
duloxetine
Duloxetine Hydrochloride
Eating disorders
Female
Humans
Inhibitor drugs
longitudinal analysis
Male
Mental depression
Middle Aged
obesity
Thiophenes - therapeutic use
Treatment Outcome
Title Duloxetine in the treatment of binge eating disorder with depressive disorders: A placebo-controlled trial
URI https://api.istex.fr/ark:/67375/WNG-P568QPVL-T/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Feat.20946
https://www.ncbi.nlm.nih.gov/pubmed/21744377
https://www.proquest.com/docview/920835236
https://www.proquest.com/docview/920784872
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWqsumGR3mFArIQqtikTWLHcWA16oMKwaigKXSBZPlxjapGCerMoMKKT-Ab-ZLaTuKqqEiIXSTfPGzfax_fHB8j9JxYBg6F89RhoTqlQGTKFVRpbv2GPaolNT418G7KDo7om-PyeAW9GvfC9PoQMeHmIyOM1z7ApZpvX4qGuqHKLe9q6uW2PVfLA6IPl9JRjPT0xaJiKaEVH1WFsmI73nllLrrhm_X8OqB5FbeGiWf_Fvo8fnLPNzndWi7Ulv7xh5rjf9bpNro5AFI86T3oDlqBdh0luyewwJt4UA1t8HQU7V9Ha3HM_H4XNbvLpjv326YBn7TYoUkcqeu4s1j5rCH2uLT9gs2g9Il98hePHNxvEAvmL_EEB5aY6n7__DXQ6BswOBwucg8d7e_Ndg7S4QCHVNOCslRKMNpApi1lTHpZIElsZsuSlLnJMmVra4BmyvVPoWhpwMFTa2sAxv3Sqib30WrbtfAQYUW0BpOrOrfgQIXlBDLCdc00r4zKSYJejF0p9KBu7g_ZaESvy1wIV1UR2jZBz6Lp117S4zqjzeAP0UKenXoOXFWKT9PX4rBk_P3hx7dilqCN0WHEEP5zURcB2RL3GBxLXdz6nzGyhW4ZTCruVotFgh70bhZf5VeJlFSVq1Nwlr9_pdibzMLFo3833UBrDvQVPY_uMVpdnC3hiQNWC_U0RNAFG4kf_Q
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaq9kAvPMorlIeFoOKSNrEdJ0HisGJbtnS7KmgLvZnYHqOqURZ1d6HlxE_gh_BX-BP8EmznURUViUsP3CJ58rA9Hn8zGX-D0BNqOFgUnoUWC-UhA1qEmYQ0jI07sMdUwbQLDeyO-GCfvT5IDhbQj_YsTM0P0QXc3Mrw9totcBeQ3jhjDbW2yvp3OeNNSuUOnH6xDtv0xXbfzu5TQrY2xy8HYVNTIFSMMB4WBWilIVKGcV44ppqCmsgkCU1iHUXS5EYDiyRlKZEs0WARkzE5AM8c2nfUS9bgL7kK4o6pv__2jKyK0zphkqQ8tLdnLY9RRDa6Tz23-y25iTy5CNqeR8p-q9u6hn62g1RnuBytz2dyXX39gz_yfxnF6-hqg7lxr14kN9ACVCso6B_CDK_hhhi1xKO2LsEKWu62hdObqOzPy8mJOxkO-LDCFjDjLjsfTwyWLjCKHfSuPmLdkJliF9_GbZrxZ-gaps9xD_tEODn59e17c1KgBI19_ZRbaP9SRuI2WqwmFdxFWFKlQMcyjw1Y3GQyChHNVM5VlmoZ0wA9a3VHqIbA3dURKUVNPU2E7arwcxmgx53op5q15CKhNa-AnURxfOTS_NJEvB-9EnsJz97svRuKcYBWWw0VjYWbipx48E7tY3DXak2T-99UVDCZe5E0sw4xCdCdWq-7VzlHmNE0tX3y2vn3rxSbvbG_uPfvoo_QlcF4dyiG26OdVbRsMS6p0wbvo8XZ8RweWBw5kw_98sXow2Vr-m_-n37h
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqVkK98CivUB4WgopL2sR2nASJw4p0aWlZLWgLvZk4HqOqUVJ1d6HlxE_gf_BX-BX8EmznURUViUsP3CJ58rA9M_7szHyD0BOqORgUnvgGC6U-A5r7iYTYD7VN2GNFzpQ9Gngz4lt77PV-tL-AfnS5MA0_RH_gZi3D-Wtr4EdKb5yRhhpXZbZ3KeNtROUOnH4x-7Xpi-3MTO5TQoabk5dbfltSwC8YYdzPc1CFgqDQjPPcEtXkVAc6imgUqiCQOtUKWCApi4lkkQIDmLROAXhiwb5lXjL-fonxILV1IrJ3Z1xVnDbxkiTmvrk96WiMArLRf-q5xW_JzuPJRcj2PFB2K93wGvrZjVET4HK4Pp_J9eLrH_SR_8kgXkdXW8SNB42J3EALUK0gLzuAGV7DLS1qiUddVYIVtNwvCqc3UZnNy_rE5oUDPqiwgcu4j83HtcbSHotiC7yrT1i1VKbYnm7jLsj4M_QN0-d4gF0YnKx_ffve5gmUoLCrnnIL7V3KSNxGi1VdwV2EJS0KUKFMQw0GNemEQkCTIuVFEisZUg8961RHFC19u60iUoqGeJoI01Xh5tJDj3vRo4az5CKhNad_vUR-fGiD_OJIfBi9EuOIJ2_H73fFxEOrnYKK1r9NRUocdKfmMbhvNY7J_m3KK6jnTiROzHaYeOhOo9b9q-w2mNE4Nn1yyvn3rxSbg4m7uPfvoo_QlXE2FLvbo51VtGwALmliBu-jxdnxHB4YEDmTD53xYvTxshX9N_n7fZA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Duloxetine+in+the+treatment+of+binge+eating+disorder+with+depressive+disorders%3A+A+placebo-controlled+trial&rft.jtitle=The+International+journal+of+eating+disorders&rft.au=Guerdjikova%2C+Anna+I&rft.au=McElroy%2C+Susan+L&rft.au=Winstanley%2C+Erin+L&rft.au=Nelson%2C+Eric+B&rft.date=2012-03-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0276-3478&rft.eissn=1098-108X&rft.volume=45&rft.issue=2&rft.spage=281&rft_id=info:doi/10.1002%2Feat.20946&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=2582848771
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0276-3478&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0276-3478&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0276-3478&client=summon